|
A multi-centric randomized phase II trial evaluating dual targeting of the EGFR with cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer (UCGI 25: A UNICANCER trial). |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Merck; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Honoraria - Amgen; Lilly; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Lilly; Roche; Sanofi |
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Ipsen; Lilly; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Lilly; Roche |
|
|
|
Honoraria - Bayer; Sanofi |
Consulting or Advisory Role - Bayer |
|
Travel, Accommodations, Expenses - Pfizer |
|
Christelle De La Fouchardiere |
Leadership - Bayer; Celgene; Roche |
Consulting or Advisory Role - Bayer |
|
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
Honoraria - Amgen; Bayer; Celgene; Lilly; Merck Serono; Roche; Sanofi; Teva |
Consulting or Advisory Role - Merck; Roche |
Travel, Accommodations, Expenses - Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - Merck; Novartis; Roche; Sanofi |
Consulting or Advisory Role - Celgene; Merck; Roche; Sanofi |
|
|
Honoraria - Ipsen; Sanofi |
Consulting or Advisory Role - Ipsen; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Baxter; BAYER; Bristol-Myers Squibb; Lilly; Merck Serono; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Roche/Genentech |
Travel, Accommodations, Expenses - Amgen; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche |
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche |